ウイルス性胃腸炎の世界市場レポート 2025年

ウイルス性胃腸炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.4％で87億3,000万米ドルに成長します。予測期間の成長は、世界ヘルスへの備え、気候変動の影響、ワンヘルスアプローチ、疫学的サーベイランスシステム、教育、国民の意識に起因すると考えられます。予測期間における主な動向には、ワクチン開発、高度診断、診断における遠隔医療、共同研究イニシアティブ、個別化医療アプローチ、デジタルヘルスソリューションなどがあります。

消化器疾患の有病率の上昇は、今後のウイルス性胃腸炎市場の成長を牽引すると予想されます。消化管（GI）疾患は、消化管のあらゆる部分に影響を及ぼす疾患です。ウイルス性胃腸炎の治療や診断ソリューションは、病気に苦しむ人々に適切な薬物療法を提供します。例えば、2023年9月、クローン病と潰瘍性大腸炎患者の生活改善に取り組むカナダを拠点とする団体IBD Clinical and Research Centreが発表した「IBDの影響レポート2023」では、2023年の有病率は10万人当たり825人と報告されています。これは、カナダで32万人以上が炎症性腸疾患（IBD）に罹患していることを意味し、年間2.44%の増加が予想されることから、2035年には人口の1.1%、すなわち47万人のカナダ人がIBDとともに暮らすことになると予測されています。したがって、胃腸疾患の有病率の上昇がウイルス性胃腸炎市場の成長を牽引しています。

衛生に対する意識の高まりが、今後のウイルス性胃腸炎市場の成長を牽引すると予想されます。衛生とは、清潔な環境を維持するための手洗い、排泄物の処理、個人の清潔さなどの個人的な習慣を指します。サニテーションとは、安全な廃棄物処理、水処理、家庭や地域社会、公共空間における衛生的な環境を確保するための設備を提供することを指します。衛生とサニテーションは、胃腸炎の原因となるウイルスのトランスミッションを防ぐために不可欠です。これらの対策は、糞便-経口感染経路を断ち切り、汚染を減らし、ウイルス性胃腸炎のアウトブレイクのリスクと影響を最小限に抑えることで、地域社会全体の健康を向上させるのに役立ちます。例えば、2024年3月、スイスに本部を置く国連機関、世界保健機関（WHO）は、2022年には世界人口の57％、すなわち46億人が安全に管理された衛生サービスを利用していると報告しました。その内訳は、33％（27億人）が処理された下水道に接続された民間施設を利用し、21％（17億人）が排泄物をその場で安全に処理するトイレや便所を利用し、全人口の88％（72億人）が少なくとも基本的な衛生サービスに依存しています。したがって、衛生と公衆衛生に対する意識の高まりが、ウイルス性胃腸炎市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウイルス性胃腸炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のウイルス性胃腸炎市場：成長率分析
• 世界のウイルス性胃腸炎市場の実績：規模と成長, 2019-2024
• 世界のウイルス性胃腸炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウイルス性胃腸炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウイルス性胃腸炎市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 制酸剤
• 下剤
• 抗運動剤
• その他医薬品
• 世界のウイルス性胃腸炎市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• 迅速便検査
• 世界のウイルス性胃腸炎市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 水様性下痢
• 腹部のけいれん
• 痛み
• その他の適応症
• 世界のウイルス性胃腸炎市場ウイルスの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ノロウイルス
• ロタウイルス
• アストロウイルス
• 腸管アデノウイルス
• 世界のウイルス性胃腸炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 製薬会社
• 診断センター
• 外来診療センター
• その他エンドユーザー
• 世界のウイルス性胃腸炎市場抗生物質の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 広域抗生物質
• 狭域スペクトル抗生物質
• ペニシリン
• マクロライド
• セファロスポリン
• 世界のウイルス性胃腸炎市場制酸剤の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトンポンプ阻害剤（PPI）
• ヒスタミン2受容体拮抗薬（H2ブロッカー）
• マグネシウムベースの制酸剤
• カルシウムベースの制酸剤
• 重炭酸ナトリウム
• 世界のウイルス性胃腸炎市場、下剤の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膨張性下剤
• 浸透圧性下剤
• 刺激性下剤
• 便軟化剤
• 世界のウイルス性胃腸炎市場、抗運動剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロペラミド
• ジフェノキシレート
• 世界のウイルス性胃腸炎市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口補水塩（Ors）
• 亜鉛サプリメント
• 制吐剤

第7章 地域別・国別分析

• 世界のウイルス性胃腸炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウイルス性胃腸炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウイルス性胃腸炎市場：競合情勢
• ウイルス性胃腸炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• C.H. Boehringer Sohn AG & Co. KG
• Mylan N.V.
• Astellas Pharma Inc.
• Fresenius Kabi AG
• Bausch Health Companies Inc.
• Alexion Pharmaceuticals Inc.
• Horizon Therapeutics Plc
• Dr. Reddy's Laboratories Ltd.
• BioMarin Pharmaceutical Inc.
• Lupin Limited
• Zydus Lifesciences Limited
• Alkem Laboratories Ltd
• Ironwood Pharmaceuticals Inc
• ANI Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウイルス性胃腸炎市場2029：新たな機会を提供する国
• ウイルス性胃腸炎市場2029：新たな機会を提供するセグメント
• ウイルス性胃腸炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Viral gastroenteritis is an intestinal viral infection characterized by swelling, irritation, and inflammation of the inner lining of the gastrointestinal tract. Common signs and symptoms include watery diarrhea, nausea or vomiting, stomach cramps, and fever.

The main types of drugs used in the treatment of viral gastroenteritis include antibiotics, antacids, laxatives, antimotility agents, and others. Antacids are medications that neutralize stomach acid to alleviate heartburn and indigestion. Diagnosis typically involves a physical examination and a rapid stool test, indicated by symptoms such as watery diarrhea, abdominal cramps, and pain. The various types of viruses associated with viral gastroenteritis include norovirus, rotavirus, astrovirus, and enteric adenovirus. These drugs and diagnostic procedures are utilized by various end-users, including hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers, and others.

The viral gastroenteritis market research report is one of a series of new reports from The Business Research Company that provides viral gastroenteritis market statistics, including viral gastroenteritis industry global market size, regional shares, competitors with a viral gastroenteritis market share, detailed viral gastroenteritis market segments, market trends, and opportunities, and any further data you may need to thrive in the viral gastroenteritis industry. This viral gastroenteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral gastroenteritis market size has grown steadily in recent years. It will grow from $6.75 billion in 2024 to $7.08 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to the prevalence of viral infections, global hygiene practices, advancements in diagnostics, global travel and tourism, and climate and environmental factors

The viral gastroenteritis market size is expected to see strong growth in the next few years. It will grow to $8.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to global health preparedness, climate change impact, one health approach, epidemiological surveillance systems, education and public awareness. Major trends in the forecast period include vaccine development, advanced diagnostics, telemedicine in diagnosis, collaborative research initiatives, personalized medicine approaches, and digital health solutions.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the viral gastroenteritis market in the future. Gastrointestinal (GI) disorders are diseases that affect any part of the gastrointestinal tract. Viral gastroenteritis treatments and diagnostic solutions provide appropriate medication for those suffering from the illness. For example, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn's disease and ulcerative colitis, reported a prevalence of 825 per 100,000 in 2023. This means that over 320,000 people in Canada have inflammatory bowel disease (IBD), and with an expected annual increase of 2.44%, it is projected that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Therefore, the rising prevalence of gastrointestinal disorders is driving the growth of the viral gastroenteritis market.

The growing awareness of hygiene and sanitation is expected to drive the growth of the viral gastroenteritis market in the future. Hygiene includes personal practices such as handwashing, waste disposal, and personal cleanliness to maintain a clean environment. Sanitation refers to providing facilities for safe waste disposal, water treatment, and ensuring a hygienic setting in homes, communities, and public spaces. Both hygiene and sanitation are essential in preventing the transmission of viruses that cause gastroenteritis. These measures help disrupt the fecal-oral transmission route, reduce contamination, and enhance overall community health by minimizing the risk and impact of viral gastroenteritis outbreaks. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based United Nations agency, reported that 57% of the global population, or 4.6 billion people, utilized safely managed sanitation services in 2022. This included 33% (2.7 billion) accessing private facilities connected to treated sewers, 21% (1.7 billion) using toilets or latrines that safely disposed of waste on-site, and 88% of the total population (7.2 billion) relying on at least basic sanitation services. Therefore, the increasing awareness of hygiene and sanitation is fueling the growth of the viral gastroenteritis market.

A prominent trend gaining momentum in the viral gastroenteritis market is product innovation. Major companies operating in this market are directing their efforts toward developing new products to fortify their market positions. For example, in November 2022, GlaxoSmithKline plc obtained approval from the US Food and Drug Administration (FDA) for an oral-dosing applicator-only presentation of ROTARIX, an oral vaccine to prevent rotavirus gastroenteritis in infants. This new presentation eliminates the need for reconstitution at the point of use, offering added convenience for healthcare providers. The approval is based on international clinical trial data demonstrating safety, tolerability, and immunogenicity compared to the lyophilized formulation.

Leading companies in the viral gastroenteritis market are introducing innovative products such as PCR kits for gastrointestinal infectious diseases to gain a competitive edge. PCR kits, also known as Polymerase Chain Reaction kits, are molecular biology tools designed for the amplification and detection of specific DNA sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd. launched 10 Real Time PCR Kits designed for the accurate detection of gastrointestinal pathogens. Covering a range of bacterial, viral, and parasitic pathogens associated with gastrointestinal infections, this solution provides a streamlined approach from sample pre-processing to PCR amplification analysis.

In January 2024, HilleVax Inc., a Switzerland-based biotech company, partnered with Chengdu Kanghua Biological Products Co. Ltd. This collaboration aims to develop HIL-216, a next-generation norovirus vaccine targeting six common genotypes, with clinical trials scheduled to begin in 2024 following FDA approval. Kanghua Biological Products Co. Ltd. is a China-based company dedicated to the development and manufacturing of biological products and vaccines for both veterinary and human health.

Major companies operating in the viral gastroenteritis market include Pfizer Inc., Abbvie Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, C.H. Boehringer Sohn AG & Co. KG, Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics Plc, Dr. Reddy's Laboratories Ltd., BioMarin Pharmaceutical Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, Ironwood Pharmaceuticals Inc, ANI Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Allergan plc, Haustus Biotech Private Limited, Gracia Lifesciences India Private Limited

North America was the largest region in the viral gastroenteritis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the viral gastroenteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral gastroenteritis market consists of revenues earned by entities by providing various diagnostics such as polymerase chain reaction testing and immunoassays. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral gastroenteritis market also includes sales of antiemetics, and chemotherapy drugs used for treating viral gastroenteritis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Gastroenteritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral gastroenteritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral gastroenteritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral gastroenteritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Antibiotics; Antacids; Laxatives; Antimotility Agents; Others Drugs
• 2) By Diagnosis: Physical Examination; Rapid Stool Test
• 3) By Indication: Watery Diarrhea; Abdominal Cramps; Pain; Other Indications
• 4) By Type Of Virus: Norovirus; Rotavirus; Astrovirus; Enteric Adenovirus
• 5) By End User: Hospitals; Clinics; Pharmaceutical Companies; Diagnostic Centers; Ambulatory Care Centers; Others End Users
• Subsegments:
• 1) By Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Penicillins; Macrolides; Cephalosporins
• 2) By Antacids: Proton Pump Inhibitors (PPIs); Histamine-2 Receptor Antagonists (H2 Blockers); Magnesium-Based Antacids; Calcium-Based Antacids; Sodium Bicarbonate
• 3) By Laxatives: Bulk-Forming Laxatives; Osmotic Laxatives; Stimulant Laxatives; Stool Softeners
• 4) By Antimotility Agents: Loperamide; Diphenoxylate
• 5) By Other Drugs: Oral Rehydration Salts (Ors); Zinc Supplements; Antiemetics
• Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Sanofi S.A.; Abbott Laboratories; GlaxoSmithKline Plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Gastroenteritis Market Characteristics

3. Viral Gastroenteritis Market Trends And Strategies

4. Viral Gastroenteritis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Viral Gastroenteritis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Gastroenteritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Gastroenteritis Market Growth Rate Analysis
• 5.4. Global Viral Gastroenteritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Gastroenteritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Gastroenteritis Total Addressable Market (TAM)

6. Viral Gastroenteritis Market Segmentation

• 6.1. Global Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antacids
• Laxatives
• Antimotility Agents
• Others Drugs
• 6.2. Global Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Examination
• Rapid Stool Test
• 6.3. Global Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Watery Diarrhea
• Abdominal Cramps
• Pain
• Other Indications
• 6.4. Global Viral Gastroenteritis Market, Segmentation By Type Of Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Norovirus
• Rotavirus
• Astrovirus
• Enteric Adenovirus
• 6.5. Global Viral Gastroenteritis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmaceutical Companies
• Diagnostic Centers
• Ambulatory Care Centers
• Others End Users
• 6.6. Global Viral Gastroenteritis Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
• Penicillins
• Macrolides
• Cephalosporins
• 6.7. Global Viral Gastroenteritis Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPIs)
• Histamine-2 Receptor Antagonists (H2 Blockers)
• Magnesium-Based Antacids
• Calcium-Based Antacids
• Sodium Bicarbonate
• 6.8. Global Viral Gastroenteritis Market, Sub-Segmentation Of Laxatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bulk-Forming Laxatives
• Osmotic Laxatives
• Stimulant Laxatives
• Stool Softeners
• 6.9. Global Viral Gastroenteritis Market, Sub-Segmentation Of Antimotility Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Loperamide
• Diphenoxylate
• 6.10. Global Viral Gastroenteritis Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Rehydration Salts (Ors)
• Zinc Supplements
• Antiemetics

7. Viral Gastroenteritis Market Regional And Country Analysis

• 7.1. Global Viral Gastroenteritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Gastroenteritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Gastroenteritis Market

• 8.1. Asia-Pacific Viral Gastroenteritis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Gastroenteritis Market

• 9.1. China Viral Gastroenteritis Market Overview
• 9.2. China Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Gastroenteritis Market

• 10.1. India Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Gastroenteritis Market

• 11.1. Japan Viral Gastroenteritis Market Overview
• 11.2. Japan Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Gastroenteritis Market

• 12.1. Australia Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Gastroenteritis Market

• 13.1. Indonesia Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Gastroenteritis Market

• 14.1. South Korea Viral Gastroenteritis Market Overview
• 14.2. South Korea Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Gastroenteritis Market

• 15.1. Western Europe Viral Gastroenteritis Market Overview
• 15.2. Western Europe Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Gastroenteritis Market

• 16.1. UK Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Gastroenteritis Market

• 17.1. Germany Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Gastroenteritis Market

• 18.1. France Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Gastroenteritis Market

• 19.1. Italy Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Gastroenteritis Market

• 20.1. Spain Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Gastroenteritis Market

• 21.1. Eastern Europe Viral Gastroenteritis Market Overview
• 21.2. Eastern Europe Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Gastroenteritis Market

• 22.1. Russia Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Gastroenteritis Market

• 23.1. North America Viral Gastroenteritis Market Overview
• 23.2. North America Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Gastroenteritis Market

• 24.1. USA Viral Gastroenteritis Market Overview
• 24.2. USA Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Gastroenteritis Market

• 25.1. Canada Viral Gastroenteritis Market Overview
• 25.2. Canada Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Gastroenteritis Market

• 26.1. South America Viral Gastroenteritis Market Overview
• 26.2. South America Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Gastroenteritis Market

• 27.1. Brazil Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Gastroenteritis Market

• 28.1. Middle East Viral Gastroenteritis Market Overview
• 28.2. Middle East Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Gastroenteritis Market

• 29.1. Africa Viral Gastroenteritis Market Overview
• 29.2. Africa Viral Gastroenteritis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Gastroenteritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Gastroenteritis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Gastroenteritis Market Competitive Landscape And Company Profiles

• 30.1. Viral Gastroenteritis Market Competitive Landscape
• 30.2. Viral Gastroenteritis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Gastroenteritis Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. C.H. Boehringer Sohn AG & Co. KG
• 31.3. Mylan N.V.
• 31.4. Astellas Pharma Inc.
• 31.5. Fresenius Kabi AG
• 31.6. Bausch Health Companies Inc.
• 31.7. Alexion Pharmaceuticals Inc.
• 31.8. Horizon Therapeutics Plc
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. BioMarin Pharmaceutical Inc.
• 31.11. Lupin Limited
• 31.12. Zydus Lifesciences Limited
• 31.13. Alkem Laboratories Ltd
• 31.14. Ironwood Pharmaceuticals Inc
• 31.15. ANI Pharmaceuticals Inc.

32. Global Viral Gastroenteritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Gastroenteritis Market

34. Recent Developments In The Viral Gastroenteritis Market

35. Viral Gastroenteritis Market High Potential Countries, Segments and Strategies

• 35.1 Viral Gastroenteritis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Gastroenteritis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Gastroenteritis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer